Treatment of patients w/ acromegaly: In whom surgery or RT is inappropriate or ineffective, or in the interim period until RT becomes fully effective. Treatment of patients w/ symptoms associated w/ functional gastro-entero-pancreatic endocrine tumors: Carcinoid tumors w/ features of the carcinoid syndrome; VIPomas; gastrinomas/Zollinger-Ellison syndrome; insulinomas, for pre-op control of hypoglycemia & for maintenance therapy; GFRomas. Treatment of patients w/ advance neuroendocrine tumors of the midgut or unknown primary tumor location.
Administered as a deep intragluteal inj. Acromegaly Initially 20 mg at 4-wk intervals for 3 mth. Gastro-entero-pancreatic endocrine tumor Initially 20 mg at 4-wk intervals. Patient on SC Sandostatin should continue at the previously effective dosage for 2 wk after the 1st inj of Sandostatin LAR every 4 wks. For patients in whom symptoms are only partially controlled after 3 mth of treatment, dose may be increased to 30 mg every 4 wks. Advanced neuroendocrine tumors of the midgut or unknown primary tumor location 30 mg 4 wkly.
Visual field defects. Monitor thyroid function in patients receiving prolonged treatment. Bradycardia. Cholethiasis & may be associated w/ cholecystitis & biliary duct dilatation. May affect glucose regulation. Post-prandial glucose tolerance may be impaired; hypoglycemia, hyperglycemia. May alter dietary fat absorption in some patients; monitor vit B12 levels during therapy. Hepatic & renal impairment. Female w/ child-bearing potential. Pregnancy & lactation. Childn <18 yr. Elderly ≥65 yr.
β-blockers, Ca channel blockers or agents to control fluid & electrolyte balance; insulin & antidiabetics; reduce intestinal absorption of ciclosporin & delay absorption of cimetidine; increase bioavailability of bromocriptine; decreases metabolic clearance of quinidine & terfenadine.
Sign Out
